Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of > or = 300/mm3: CPCRA 059.

Source:http://linkedlifedata.com/resource/pubmed/id/11873071

J. Acquir. Immune Defic. Syndr. 2002 Mar 1 29 3 221-31

Download in:

View as

Triples

General Info

PMID
11873071